Artiva Biotherapeutics, Inc..
ARTV.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Artiva Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing allogeneic cell therapies for the treatment of cancer. The company's pipeline includes AlloNK® cell therapy programs and CAR-T programs. These therapies are designed to leverage the innat...Show More
Better Health for All
10
Artiva Biotherapeutics' core mission is to develop effective, safe, and accessible cell therapies for devastating autoimmune diseases and cancers, with its entire product portfolio devoted to health improvement.
1
Preclinical and early clinical data for its therapies, such as AlloNK, show promising outcomes, including a 64% complete response rate in B-cell non-Hodgkin lymphoma patients and a median duration of response of at least 19.4 months.
2
The company has no revenue from products with established negative health outcomes.
3
While clinical trials report common treatment-emergent adverse events like neutropenia (84%) and leukopenia (82%), and serious adverse events such as febrile neutropenia (7%) and infusion-related reactions (7%), there were no immune effector cell-associated neurotoxicity syndrome, graft-versus-host disease, deaths, or trial discontinuations due to AlloNK-related adverse events.
4
However, specific adverse event rates per million users are not provided, preventing a score above 0. The company's research and development expenses were $50.3 million for the year ended December 31, 2024,
5
and $17.1 million for Q1 2025,
6
representing 100% of its operational expenses excluding general and administrative costs. Clinical trials are approved by regulatory bodies such as the Australian Human Research Ethics Committee
7
and the Korean Ministry of Food and Drug Safety,
8
and AlloNK has received FDA Fast Track designation for lupus nephritis and B-cell non-Hodgkin lymphoma.
9
Fair Money & Economic Opportunity
0
Artiva Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing cell therapies, not a financial institution.
1
The company does not offer lending, deposit, or other financial services to consumers. Therefore, all KPIs related to financial products, pricing, fees, lending practices, customer financial data, wealth-building outcomes, and financial literacy initiatives are not applicable to its core business model. While the company aims to make its medical therapies broadly accessible to underserved patient populations and reduce treatment costs,
2
this does not align with the definition of 'Fair Money & Economic Opportunity' which specifically evaluates financial institutions and services. The company's commitment to Pledge 1% involves donating 1% of product, equity, profit, or employee time to causes,
3
which is a philanthropic activity, but not specifically reinvestment in community finance or profit-sharing with underserved communities as defined by the rubric.
Fair Pay & Worker Respect
0
The company has no public record of labor-law breaches, regulatory actions, violations, or fines mentioned in the provided articles.
1
The Compensation Committee's responsibilities include monitoring regulatory compliance with respect to compensation matters.
2
No specific, quantitative data was found for living wage coverage, CEO to median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, insecure contract share, or health insurance coverage.
3
While 'Health and retirement benefits' were listed as a 'Con' in employee reviews, no specific coverage percentage was provided.
4
Fair Trade & Ethical Sourcing
0
No specific, concrete evidence was found in the provided articles to assess Artiva Biotherapeutics, Inc. against any of the Fair Trade & Ethical Sourcing KPIs. The articles primarily consist of financial filings, job descriptions, and a general code of business conduct, none of which provide quantitative data or specific details on supplier fair trade certifications, audit frequencies for ethical sourcing, incidents of forced or child labor in the supply chain, traceability coverage, remediation speed for violations, ethical clauses in supplier contracts, materials risk index, or supplier diversity spend.
1
Honest & Fair Business
-30
The company has a Code of Business Conduct and Ethics, which is posted on its website, and conducts annual training sessions.
1
A toll-free compliance hotline and an anonymous reporting website are available, managed by a trained third-party vendor, with confidentiality maintained.
2
The company explicitly states it does not restrict current or former employees from communicating or filing complaints with U.S. federal, state, or local governmental entities regarding possible violations of law, provided disclosures are consistent with applicable law and not subject to attorney-client privilege unless permitted.
3
The Compliance Officer is responsible for promptly investigating all reported possible Code violations.
4
The company has an Anti-Corruption Policy requiring compliance with the Foreign Corrupt Practices Act (FCPA), and sets a gift and entertainment value limit of no more than $300.00.
5
Kind to Animals
0
No specific, concrete data points were found in the provided articles to assess Artiva Biotherapeutics against any of the 'Kind to Animals' KPIs. The articles primarily focus on financial results, IPO details, and the company's core business of developing allogeneic cell therapies from human NK cells, with no explicit mention of animal testing policies, cruelty-free certifications, animal-derived ingredients, or animal welfare initiatives or collaborations.
1
No War, No Weapons
0
Artiva Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases and cancer.
1
The company's core business activities, as described across all provided articles, do not involve arms manufacturing, military contracts, dual-use technologies, or any other defense-related operations.
2
Consequently, all relevant KPIs are scored as N/A (Not Applicable) because the company's business model inherently falls outside the scope of defense or arms-related activities. No evidence was found to suggest any involvement in areas that would require specific policies or disclosures related to war or weapons.
3
Planet-Friendly Business
0
No specific, concrete data points or actions related to environmental performance, emissions, renewable energy, waste, water usage, certifications, or climate-related targets were found in the provided articles.
1
The articles primarily focus on financial information, regulatory actions for clinical trials, and a general commitment to the 'Pledge 1%' movement. This movement is a pledge to donate 1% of product, profit, equity, or time, and is not evidence of specific environmental actions or outcomes relevant to the defined KPIs.
2
Respect for Cultures & Communities
0
No specific, concrete evidence was found in the provided articles to assess Artiva Biotherapeutics against the defined KPIs for 'Respect for Cultures & Communities'. Information regarding pledges or internal compliance hotlines does not directly provide quantitative data or specific actions related to community engagement, cultural preservation, or local impact as required by the rubric's KPIs.
Safe & Smart Tech
0
The company's Code of Business Conduct and Ethics prohibits unauthorized access to computer systems and unlawful acts using company equipment, and its Compliance Officer is responsible for investigating possible violations.
1
The privacy policy, last updated June 5, 2020, also mentions investigating potential violations.
2
There are no documented incidents of unauthorized data use for Artiva Biotherapeutics, Inc.
3
The company's Code of Business Conduct and Ethics emphasizes obeying domestic and foreign laws, including the Foreign Corrupt Practices Act, and mentions compliance with U.S. Food and Drug Administration regulations.
4
Its privacy policy states compliance with the CAN-SPAM Act and the California Online Privacy Protection Act (CalOPPA), and that it does not knowingly collect data from children under 18.
5
The Audit Committee Charter also states that the committee provides oversight assistance for the company’s legal, risk, regulatory, and ethical compliance programs.
6
There is no evidence of regulatory penalties or specific compliance failures for Artiva Biotherapeutics, Inc.
7
Zero Waste & Sustainable Products
0
Artiva Biotherapeutics' research and development activities involve the controlled use of potentially hazardous chemical and biological materials.
1
The company and its suppliers are subject to federal, state, and local laws and regulations governing the use, manufacture, storage, handling, and disposal of medical and hazardous materials.
2
There is no evidence of any waste disposal violations.
3